Efficacy of a novel tricyclic topoisomerase inhibitor in a murine model of Neisseria gonorrhoeae infection

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5592-5594

  Savage, Victoria J ^a   Charrier, Cédric ^a   Salisbury, Anne Marie ^a   Box, Helen ^a   Chaffer Malam, Nathan ^a   Huxley, Anthony ^a   Kirk, Ralph ^a   Noonan, Gary M ^a   Mohmed, Sarfraz ^a   Craighead, Mark W ^a   Ratcliffe, Andrew J ^a   Best, Stuart A ^a   Stokes, Neil R ^a  

^a REDX PHARMA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DNA TOPOISOMERASE INHIBITOR; DOXYCYCLINE; GEPOTIDACIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; STREPTOMYCIN; TETRACYCLINE; TRIMETHOPRIM SULFATE; VANCOMYCIN; ZOLIFLODACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; GONORRHEA; IN VIVO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; NEISSERIA GONORRHOEAE;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; GONORRHEA; MICE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; TOPOISOMERASE INHIBITORS;

EID: 84983243111     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00913-16     Document Type: Article

References (15)

1. World Health Organization. 2012. Global incidence and prevalence of selected curable sexually transmitted infections-2008. World Health Organization, Geneva, Switzerland.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
3. Unemo M, Shafer WM. 2014. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587-613. http://dx.doi.org/10.1128/CMR.00010-14.
4. Unemo M. 2015. Current and future antimicrobial treatment of gonorrhoea: the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 15:364. http://dx.doi.org/10.1186/s12879-015-1029-2.
5. Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolone no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56:332-336.
6. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen Rep 64(RR-03):1-137.
7. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayam S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhoea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538-3545. http://dx.doi.org/10.1128/AAC.00325-11.
8. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. 2012. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56:1273-1280. http://dx.doi.org/10.1128/AAC.05760-11.
9. Morita-Ishihara T, Unemo M, Furubayashi K, Kawahata T, Shimuta K, Nakayama S, Onishi M. 2014. Treatment failure with2gof azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. J Antimicrob Chemother 69:2086-2090. http://dx.doi.org/10.1093/jac/dku118.
10. Savage VJ, Charrier C, Salisbury A-M, Moyo E, Forward H, Chaffer-Malam N, Metzger R, Huxley A, Kirk R, Uosis-Martin M, Noonan G, Mohmed S, Best SA, Ratcliffe AJ, Stokes NR. 2016. Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV. J Antimicrob Chemother 71:1905-1913. http://dx.doi.org/10.1093/jac/dkw061.
11. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman E, Jakielaszek C, Sahm DF. 2016. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60:1918-1923. http://dx.doi.org/10.1128/AAC.02820-15.
12. Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV. 2015. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci Rep 5:11827. http://dx.doi.org/10.1038/srep11827.
13. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Jerse AE. 1999. Experimental gonococcal genital tract infection and opacity protein expression in estradiol-treated mice. Infect Immun 67:5699-5708.
15. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.